

CUMULATIVE INDEX 1997

Volume 8

January	ADVANCES IN CLINICAL RESEARCH, pages 1-212
April	INFECTIOUS DISEASES IN DERMATOLOGY, pages 213-354
July	LASERS IN DERMATOLOGY, pages 355-548
October	ANALYSIS AND TREATMENT OF THE AGING FACE, pages 549-719

Note: Page numbers of article titles are in **boldface** type.

- Acetone, as degreasing agent, before medium-depth chemical peels, 23
- Acitretin, for psoriasis, 62
- Acne, **97-109**
- pathophysiology of, 98-104
 - follicular hyperkeratinization in, 98-99
 - inflammation in, 104
 - sebum production in, 99-104
 - psychosocial impact of, 97-98
 - scarring due to, 104-105
 - treatment of, 105-107
 - isotretinoin in, 105-106
 - topical retinoids in, 106-107
- Acquired vascular lesions, laser therapy for, **385-396**
- argon-pumped tunable dye lasers in, 385-386, 388
 - cherry angiomas, 393
 - continuous wave argon lasers in, 385, 388, 393
 - copper vapor and copper bromide lasers in, 386, 388-389
 - facial telangiectasia, 388-389
 - flashlamp-pumped pulsed dye lasers in, 386-387
 - krypton lasers in, 386
 - KTP lasers in, 386
 - leg telangiectasia, 393-395
 - poikiloderma of Civatte, 391-392
 - pulsed dye lasers in, 387-394
 - pyogenic granulomas, 392-393
 - rosacea-associated telangiectasia and erythema, 389-390
 - spider angiomas, 390-391
 - venous lakes, 393
- Acrodermatitis chronica atrophicans, clinical features of, 253-254
- Acrylates, and contact dermatitis, 146
- Actinic cheilitis, laser therapy for, 494
- Actinic keratoses, laser therapy for, 494-495
- photodynamic therapy for, 514
- Acyclovir, during pregnancy and lactation, 201
- for herpes simplex, 191, 224
 - with HIV infection, 268
 - for herpes zoster, with HIV infection, 268-269
 - for varicella zoster, 190
- Adapalene, for acne, 106-107
- for aging skin, 562
- Adeno-associated virus, gene transfer in, 31
- Adenovirus, gene transfer in, 31
- Adnexal carcinoma, microcystic, CD34 antigen expression in, 169-170
- Adnexal lesions, CD34 antigen expression in, 168-169
- Adriamycin, for postherpetic neuralgia, 191
- Aging dentition, cosmetic options for, **673-678**
- implants, 675-676
 - oral and maxillofacial surgery, 676-678
 - loss of teeth in, 674-676
 - shifting teeth in, 675-676
 - wear and attrition of teeth in, 673-674
- Aging face. *See also* *Aging skin*.
- and male pattern alopecia. *See* *Male pattern alopecia*.
 - blepharoplasty for. *See* *Blepharoplasty*.
 - brow rejuvenation surgery for. *See* *Brow rejuvenation surgery*.
 - dentition in. *See* *Aging dentition*.
 - facialplasty for. *See* *Facialplasty*.
 - in persons of color. *See* *Persons of color*.
 - perioral area in. *See* *Perioral area*.
 - rhinoplasty for. *See* *Rhinoplasty*.
 - surgical pearls in, **679-685**
 - anesthesia experience, 679-680
 - bleeding and bruising, 680-681
 - consents, 681
 - drains, 681
 - edema, 681
 - extras, 684
 - face-lift techniques, 681
 - good surgical experience, 681-682
 - hair loss, 682
 - infection, 682
 - kindness, 682
 - laser resurfacing, 682
 - magic, 682-683
 - nausea, 683
 - oxygen, 683
 - pain, 683
 - quality package matters, 683
 - respect boundaries, 683
 - scar prevention, 683
 - triangle of beauty, 684
 - unhappy and unrealistic patients, 684
 - vascularity, 684
 - warm patients, 684

- Aging face (*Continued*)
 your appearance, 684
 zigzag incisions, 684-685
- Aging skin. See also *Aging face*.
 demographics and psychological implications of, 549-553
 appearance and, 550-551
 impact of aging, 551-552
 skin disorders and, 550
 physiologic and structural changes in, 555-559
 and aesthetic damage, 558
 clinical signs of, 555-556
 microscopy of, 556
 preoperative assessment of, 583-593
 aging of other organs and, 583-584
 foreign objects and, 587-589
 medications and, 585-587
 patient competence and, 589
 protocol for, 589-592
 underlying illnesses and, 584-585
 resurfacing of, 569-582
 carbon dioxide laser therapy in. See *Carbon dioxide laser therapy*.
 chemical peels in. See *Chemical peels*.
 dermabrasion in. See *Dermabrasion*.
 rhytides. See *Rhytides*.
 topical treatment of, 561-567
 alpha-hydroxy acids in, 563-564
 ascorbic acid in, 564-565
 hormonal therapy in, 565-566
 retinoids in, 561-562
- Albendazole, during pregnancy and lactation, 199
- Allergic reactions, to laser therapy, for tattoos, 411, 528, 529
- Alopecia, androgenetic. See *Androgenetic alopecia*.
 hot-comb, in persons of color, 689
 male pattern. See *Male pattern alopecia*.
 photodynamic therapy for, 515
- Alpha-hydroxy acids, for acne, 107
 for aging skin, 563-564
 for photoaging, 432, 433
 in superficial chemical peels, 19-20
- Alternate nucleoside reverse transcriptase inhibitors, for HIV infection, 322-324
- American Academy of Pediatrics guidelines, for drugs during pregnancy and lactation, 198
- Aminolevulinic acid, in hair removal, 476
 in photodynamic therapy, 509-516
- Amorolfine, for onychomycosis, 122-123
- Androgenetic alopecia, 37-43
 biochemical advances in, 37-38
 clinical observations of, 38-39
 treatment of, 39-42
- Androgens, in acne, 99-102
- Anesthesia, in laser therapy, for atrophic scars, 451-452
 for rhytides, 442-444
 for tattoos, 415
- Anogenital infections, human papillomavirus in, 332, 333
- Anthracyclines, for Kaposi's sarcoma, 181-182
- Antibiotic prophylaxis, and cutaneous surgery, in elderly, 587-588
 in hair restoration surgery, for male pattern alopecia, 615
- Anti-CD4 monoclonal antibody, for psoriasis, 65
- Anticoagulant agents, and cutaneous surgery, in elderly, 586
- Antifungal agents, drug interactions with, 535-544
 biotransformation and, 536-538
 drug distribution and, 536
 drug elimination and, 538
 gastrointestinal absorption and, 536
 griseofulvin, 538
 imidazoles, 538-539
 pharmacokinetic versus pharmacodynamic, 535-536
 terbinafine, 539
 for onychomycosis. See *Onychomycosis*.
- Antihistamines, during pregnancy and lactation, 201-202
- Antimicrobial therapy, for necrotizing fasciitis, 217
 for rickettsialpox, 317
- Antineoplastic agents, and cutaneous surgery, in elderly, 586-587
- Antiplatelet agents, and cutaneous surgery, in elderly, 586
- Antiretroviral therapy, for HIV infection, 319-329
 future of, 326
 human immunodeficiency protease inhibitors, 324-326
 quantitative techniques in, 320
 reverse transcriptase inhibitors, 320-324
 alternate nucleoside reverse transcriptase inhibitors, 322-324
 combinations of nucleoside analogues, 323-324
 nonnucleoside reverse transcriptase inhibitors, 324
 zidovudine, 320-322
 virus pathogenesis and, 319-320
- Antithyroid thioureylenes, for psoriasis, 61
- Antiviral therapy, for human papillomavirus infections, 337-339
 for Kaposi's sarcoma, 184
 with growth factors and chemotherapy, for Kaposi's sarcoma, 181
- Apolipoprotein E, for Kaposi's sarcoma, 184
- Argon lasers. See also *Laser therapy*.
 basic principles of, 362-364
 complications of, 522
- Argon-pumped dye lasers. See also *Laser therapy*.
 basic principles of, 365
 complications of, 522-523
- Ascorbic acid, for aging skin, 564-565
- Aspergillosis, in immunocompromised host, 299
- Atrophic scars, laser resurfacing of, 449-457
 anesthesia in, 451-452
 carbon dioxide lasers in, 449-450
 complications of, 455-456
 histologic studies of, 460-464
 indications for, 450-451
 informed consent for, 451
 laser-tissue interaction in, 459-460
 patient selection for, 450-451
 postoperative care for, 452-453
 preoperative preparation for, 451
 results of, 453
 technique for, 452
- Autoimmune endocrine disorders, and vitiligo vulgaris, 70-71
- Autoimmune skin diseases, anti-inflammatory drugs for, 695-705
 bullous pemphigoid, 696-698
 cicatricial pemphigoid, 698-699
 connective tissue diseases, 701-702
 dermatitis herpetiformis and linear IgA bullous dermatosis, 700
 generic approach to, 700-701
 miscellaneous and reactive neutrophilic dermatoses, 704
 pemphigus, 699-700
 vasculitis, 702-704

- pathology of, 695-696
- Autologous blood products, in wound healing, 52
- Autologous fat transplantation, for rhytides. See *Rhytides*.
- Bacillary angiomatosis, with HIV infection, 273-274
- Bacterial infections, 341-349
- cellulitis/erysipelas, 343-344
 - folliculitis, 345-346
 - impetigo, 341-343
 - lymphangitis, 344-345
 - necrotizing fasciitis. See *Necrotizing fasciitis*.
 - with HIV infection. See *HIV infection*.
- Bacterial vaginosis, diagnosis and treatment of, 243-244
- Baker-Gordon solution, in deep chemical peels, 25, 573
- in skin resurfacing, versus other techniques, 461
- Bartholinitis, chlamydial infections and, 241
- Basal cell carcinoma, CD34 antigen expression in, 169-170
- photodynamic therapy for, 511-513
- Basal cell nevus syndrome, photodynamic therapy for, 513
- Benzathine penicillin G, for syphilis, 225, 226
- in females, 234
 - with HIV infection, 275
- Benzoporphyrin derivative verteporfin, in photodynamic therapy, 510
- Benzoyl peroxide, during pregnancy and lactation, 201
- Bichloroacetic acid, for human papillomavirus infections, 335
- Bifonazole and urea combination, for onychomycosis, 124
- Biologic response modifiers, for cutaneous T-cell lymphoma, 154-155
- Bio-occlusive dressings, in wound care, after laser skin resurfacing, 444-445
- Biopsies, of necrotizing fasciitis, 216
- Black widow spider bites, management of, 310-311
- Bleaching agents, before medium-depth chemical peels, 23
- Bleeding diathesis, and cutaneous surgery, in elderly, 584
- Blepharoplasty, 635-647
- anatomy in, 636-638
 - lower eyelid, 636
 - upper eyelid, 636-638
 - complications of, 645-646
 - in persons of color, 692-693
 - postoperative care for, 644-645
 - technique for, 639-644
 - lower eyelid, 643-644
 - upper eyelid, 639-641
- Blood products, in wound healing, 52
- Borrelia burgdorferi* infections, 247-255
- acrodermatitis chronica atrophicans, 253-254
 - borrelial lymphocytoma, 253
 - Lyme disease, clinical features of, 248-249
 - differential diagnosis of, 252
 - geographic distribution of, 247-248
 - laboratory diagnosis of, 250-251
 - pathology of, 249-250
 - prevention of, 253
 - treatment of, 251-253
- Botulinum A exotoxin, for rhytides. See *Rhytides*.
- Bovine collagen, injectable, for rhytides. See *Rhytides*.
- Bowen's disease, laser therapy for, 495
- photodynamic therapy for, 513
- Brow rejuvenation surgery, 623-634
- anatomy in, 624-625
 - patient evaluation for, 624-625
 - technique for, 625, 627-629
- Brown recluse spider bites. See *Spider bites*.
- Budesonide, in patch testing, for contact dermatitis, 141
- Bullous pemphigoid, anti-inflammatory drugs for, 696-698
- Café-au-lait macules, laser therapy for, 4
- Calcipotriene, for psoriasis, 62
- Cancer patients, fungal infections in. See *Immunocompromised host*.
- Candidiasis, diagnosis and treatment of, 244
- in immunocompromised host, 298-299
 - laser skin resurfacing and, 441-442
- Cantharidin, for human papillomavirus infections, 336
- Capillary hemangiomas, laser therapy for, 2-3, 14
- Capsaicin, for psoriasis, 61-62
- Carbolic acid, in deep chemical peels, 573
- Carbon dioxide ice, in medium-depth chemical peels, 20-21, 23
- Carbon dioxide laser therapy, for facial wrinkles, 5, 15
- in hair transplantation, 5-6
 - in skin resurfacing, 578-581
 - complications of, 581
 - indications and contraindications for, 579-580
 - patient selection for, 579
 - postoperative care for, 580-581
 - protocol for, 580
- Carbon dioxide lasers. See also *Laser therapy*.
- basic principles of, 361-362
 - complications of, 523, 529-531
 - in blepharoplasty, 640-643
 - laser-tissue interaction with, 487-488
 - safety of, 488-489
- Carcinoma, basal cell, CD34 antigen expression in, 169-170
- microcystic adnexal, CD34 antigen expression in, 169-170
- Cardiac pacemakers, and cutaneous surgery, in elderly, 587
- CD34 antigen expression, 159-176
- cutaneous tumor immunoreactivity to, 160
 - historical aspects of, 159-160
 - in adnexal lesions, 168-169
 - in basal cell carcinoma, 169-170
 - in fibrous and fibrohistiocytic lesions, 165-168
 - in melanocytic lesions, 172
 - in microcystic adnexal carcinoma, 169-170
 - in muscle lesions, 172
 - in neural lesions, 170-172
 - in oral submucosa and fibrovascular lesions, 172-173
 - in trichoepitheliomas, 169-170
 - in vascular lesions, 160-165
- Cellex-C, for aging skin, 564-565
- Cellulitis, diagnosis and treatment of, 343-344
- Cerebrovascular accidents, and cutaneous surgery, in elderly, 585
- Cervicitis, gonococcal, diagnosis and treatment of, 239-240
- nongonococcal, diagnosis and treatment of, 240-242
- Chancroid, diagnosis and treatment of, 226-227
- in females, 234-237
- Cheilitis, actinic, laser therapy for, 494
- Chemical avulsion, for onychomycosis, 125
- Chemical peels, in skin resurfacing, 569-575
- advances in, 19-26
 - deep, 25, 573, 575

- Chemical peels (*Continued*)
 medium-depth, 20-21, 23-25, 571-573
 superficial, 19-20, 570-571
 in persons of color, 691, 692
 for dermatosis papulosis, 689
- Chemotherapy, for cutaneous malignant melanoma, 13-14
 for human papillomavirus infections, 335-337
 for Kaposi's sarcoma, 181
- Cherry angiomas, laser therapy for, 393
- Chlamydial infections, diagnosis and treatment of, 240-242
- Chloasma, in persons of color, 690-691
- Chloramphenicol, during pregnancy and lactation, 199
- Chromos 694, in hair removal, 475
- Cicatricial pemphigoid, anti-inflammatory drugs for, 698-699
- Ciclopirox olamine, for onychomycosis, 123-124
- Cidofovir, for human papillomavirus infections, 222, 338
- Cimetidine, during pregnancy and lactation, 199
 for androgenetic alopecia, 40
 for human papillomavirus infections, 192, 336-337
- Ciprofloxacin, during pregnancy and lactation, 199
- Clarithromycin, during pregnancy and lactation, 199-200
- Cocamidopropyl betaine, and contact dermatitis, 145
- Coccidioidomycosis, in immunocompromised host, 300-301
- Collagen, injectable bovine, for rhytides. *See Rhytides.*
- Complement fixation test, for rickettsialpox, 316
- Compositae family of plants, and contact dermatitis, 140-141
- Composite grafts, in wound healing, 46-49
- Computer pattern generator, in skin resurfacing, 435, 436, 452, 460
- Condyloma acuminatum, diagnosis and treatment of, 221-223
 laser therapy for, 493-494
- Conjunctivitis, chlamydial, versus silver nitrate conjunctivitis, 241
- Connective tissue diseases, anti-inflammatory drugs for, 701-702
 CD34 antigen expression in, 173-174
- Contact dermatitis, 137-148
 epidemiology of, 138-139
 gold and, 142, 144
 hair products and, 145-146
 laser skin resurfacing and, 530
 nail products and, 146
 nickel and, 144
 palladium and, 144
 patch testing for, 137
 outcomes analysis in, 140
 reliability and technique for, 139-140
 sensitivity, specificity, and positive predictive value of, 137-138
 validity and utility of, 138
 photoallergens and, 140-141
 preservatives and, 144-145
 prevention of, barrier creams in, 144
 topical corticosteroids and, 141-142
- Continuous wave visible light lasers, basic principles of, 362
 complications of, 522-526
- Contraceptives, failure of, dermatologic drugs and, 199
 oral, for androgenetic alopecia, 41
- Copper vapor lasers. *See also Laser therapy.*
 basic principles of, 364-365
 complications of, 523, 526
- Coronary heart disease, and cutaneous surgery, in elderly, 584
- Corticosteroids, during pregnancy and lactation, 202
 topical, and contact dermatitis, 141-142
- Cosmetics, for persons of color, 691
- Coumadin, and cutaneous surgery, in elderly, 586
- Crow's feet, botulinum A exotoxin injection for, 604
- Cryotherapy, for dermatosis papulosis nigra, in persons of color, 689
 for human papillomavirus infections, 192, 222
 for Kaposi's sarcoma, 181
 for molluscum contagiosum, with HIV infection, 270
- Cryptococcosis, in immunocompromised host, 300
 with HIV infection, 277
- CTLA4Ig, for psoriasis, 64-65
- Cutaneous T-cell lymphoma, 149-157
 cutaneous lymphoid antigen expression in, 149-150
 diagnosis of, 152
 immunology of, 150-152
 staging of, 152-153
 treatment of, 153-155
- Cyclosporine, during pregnancy and lactation, 200
 for psoriasis, 63-64
- Cyproterone acetate, for androgenetic alopecia, 41
- Cytochrome C450 system, and drug biotransformation, 536-540
- Cytodestructive techniques, for human papillomavirus infections, 335
- Cytokine inhibitors, for Kaposi's sarcoma, 184
- Cytokines, for Kaposi's sarcoma, 182
 for psoriasis, 65
 in acne, 99
- Cytomegalovirus infection, with HIV infection, 267
- DAB-IL-2, for cutaneous T-cell lymphoma, 154-155
- DAB₉₀IL-2, for psoriasis, 64
- Dapsone, during pregnancy and lactation, 201
- Daunorubicin, for Kaposi's sarcoma, 182
- Degreasing agents, before medium-depth chemical peels, 23
- Dehydroepiandrosterone sulfate, in acne, 100-101
- Delavirdine, for HIV infection, 324
- Dermabrasion, in skin resurfacing, 575-578
 equipment and anesthesia for, 575-576
 indications and contraindications for, 575
 postoperative care for, 576-577
 sequelae and complications of, 577-578
 technique for, 576
 versus other techniques, 461
- Dermal lesions, laser therapy for, 497-500
 benign lesions, 497, 499-500
 lymphangioma circumscriptum, 499
 rhinophyma, 497
 tattoos. *See Tattoos.*
- Dermatitis, contact. *See Contact dermatitis.*
 seborrheic, in persons of color, 690
- Dermatitis herpetiformis, anti-inflammatory drugs for, 700
- Dermatofibromas, CD34 antigen expression in, 165, 167-168
- Dermatofibrosarcoma protuberans, CD34 antigen expression in, 165, 167-168
- Dermatologic drugs, during pregnancy and lactation, 197-206
 acyclovir, 201
 albendazole, 199
 and contraceptive failure, 199
 antihistamines, 201-202

- benzoyl peroxide, 201
 chloramphenicol, 199
 cimetidine, 199
 ciprofloxacin, 199
 clarithromycin, 199-200
 corticosteroids, 202
 cyclosporine, 200
 dapsone, 201
 doxepin, 200
 general prescribing rules for, 203
 griseofulvin, 200
 hydroxyzine, 200
 interferons, 200
 metronidazole, 200
 monoxidil, 200
 nonsteroidal anti-inflammatory drugs, 200
 opioid narcotics, 201
 podophyllum, 200
 rifampin, 200
 salicylic acid, 200
 selenium sulfide, 200
 silver sulfadiazine, 201
 sources for determination of risk, 197-198
 spironolactone, 200
 sulfonamides, 201
 tretinoin, 202-203
 trimetoprim, 201
- Dermatologic research, advances in, *acne*. See *Acne*.
androgenetic alopecia. See *Androgenetic alopecia*.
 CD34 antigen expression. See *CD34 antigen expression*.
 chemical peels. See *Chemical peels*.
 contact dermatitis. See *Contact dermatitis*.
 cutaneous T-cell lymphoma. See *Cutaneous T-cell lymphoma*.
 dermatologic surgery. See *Dermatologic surgery*.
 dermoscopy. See *Dermoscopy*.
 gene therapy. See *Gene therapy*.
 in children. See *Pediatric dermatology*.
 Kaposi's sarcoma. See *Kaposi's sarcoma*.
 laser therapy. See *Laser therapy*.
 onychomycosis. See *Onychomycosis*.
 psoriasis. See *Psoriasis*.
 viral diseases. See *Viral diseases*.
 vitiligo vulgaris. See *Vitiligo vulgaris*.
 wound healing. See *Wound healing*.
- Dermatologic surgery, advances in, 9-18
 for cutaneous malignant melanoma, 9-14
 epidemiology and diagnosis, 9-11
 treatment, 11-14
 laser therapy. See *Laser therapy*.
 tumescent liposuction, 15-16
 tumorigenesis, 16
- Dermatophytosis, in immunocompromised host, 296, 298
- Dermatoses, anti-inflammatory drugs for, 700, 704
- Dermatosis papulosis nigra, in persons of color, 688-689
- Dermoscopy, advances in, 79-95
 application of principles and techniques, 81-89
 qualitative analysis of images, 82
 qualitative analysis with risk stratification, 82, 84
 qualitative analysis with semiquantitative methods, 84, 87
 qualitative analysis with statistical methods, 87
 biophysical aspects, 79-80
 clinical studies, 89-92
 diagnostic performance, 91
 evaluation by user groups, 92
 evaluation of different analysis methods, 89, 91
 evaluation of single criterion, 89
 indications and limitations of techniques, 92
 computer-assisted imaging, 87, 89
 diagnostic criteria, 80-81
 future applications, 92-93
 technical aspects, 80
- Dexamethasone, for androgenetic alopecia, 40-41
- Diabetes, and cutaneous surgery, in elderly, 584-585
- Diazolidinyl urea, and contact dermatitis, 145
- Didanosine, for HIV infection, 193, 322-324
- Diuretics, and cutaneous surgery, in elderly, 587
- Donovanosis, diagnosis and treatment of, 227-228
 in females, 237-238
- Dovonex, for psoriasis, 62
- Doxepin, during pregnancy and lactation, 200
- Doxorubicin, for Kaposi's sarcoma, 194
- Drug interactions, and cutaneous surgery, in elderly, 587
- Ecthyma, clinical features of, 342
- Ecthyma gangrenosum, with HIV infection, 273
- Ectoparasitic infections, in world travelers, 286-287
- Ectropion, of lower eyelid, laser skin resurfacing and, 531
- Electrical stimulation, in wound healing, 54
- Electrodesiccation, for dermatosis papulosis, in persons of color, 689
- Electrolysis, in hair removal. See *Hair removal*.
- Electromyography, to guide botulinum A exotoxin injections, for rhytides, 605
- Electron beam radiotherapy, for cutaneous T-cell lymphoma, 154
 with extracorporeal photochemotherapy, for cutaneous T-cell lymphoma, 154
- Electrosurgery, for human papillomavirus infections, 334
- Endocrine disorders, autoimmune, and vitiligo vulgaris, 70-71
- Eneidyne, for Kaposi's sarcoma, 184
- Enzyme immunoassays, of Lyme disease, 250
- Enzyme therapy, for varicella zoster, 190-191
- Epidermal allografts, in wound healing, 46
- Epidermal autografts, in wound healing, 45-46
- Epidermal growth factor, in wound healing, 50
- Epidermal lesions, laser therapy for, 494-497
 actinic cheilitis, 494
 actinic keratoses, 494-495
 carbon dioxide lasers in, 489
 inflammatory conditions, 496-497
 nevi, 496
 seborrheic keratoses and lentigines, 496
 skin cancer, 495-496
 wound care in, 489
- Epididymitis, chlamydial infections and, 241
- EpiLaser, in hair removal, 474-475
- Epiluminescence microscopy. See *Dermoscopy*.
- EpiTouch, in hair removal, 475
- Epstein-Barr virus infection, with HIV infection, 269
- Eruptive pseudoangiomatosis, in children, 261-262
- Er:YAG lasers. See also *Laser therapy*.
 basic principles of, 502
- Erysipelas, diagnosis and treatment of, 343-344
- Erythema infectiosum, in children, 260-261
- Erythema migrans, in Lyme disease, 248-249
- Erythroplasia of Queyrat, laser therapy for, 495-496
- Estrogen replacement therapy, for aging skin, 565-566
- Ethocyn, for aging skin, 565-566
- Eulexin, for androgenetic alopecia, 40
- Exanthematous diseases, in children, 257-266

Exanthematous diseases (*Continued*)

- eruptive pseudoangiomatosis, 261-262
- Kawasaki syndrome, 262-263
- measles, 257-259
- parvovirus B19, 260-261
- unilateral laterothoracic exanthem, 261
- varicella, 259-260
- Exanthems, viral, treatment of, 189
- Extracorporeal photochemotherapy, with electron beam radiotherapy, for cutaneous T-cell lymphoma, 154
- Eyelids, ectropion of, laser skin resurfacing and, 531
- rejuvenation surgery for. *See* *Blepharoplasty*.
- Face lift, ancillary procedures with, chemical peels, 23
- Facial hair, increased, in persons of color, 689-690
- Facial telangiectasia, laser therapy for, 388-389
- Facial wrinkles, laser therapy for, 5
- Facialplasty, 649-658
 - ancillary procedures with, 657
 - chemical peels, 23
 - anesthesia in, 651-652
 - consultation for, 651
 - contraindications to, 650-651
 - gender differences in, 657
 - in persons of color, 693
 - indications for, 649-650
 - postoperative care for, 654-655
 - preoperative preparation for, 651-652
 - technique for, 652-654
- Famciclovir, for varicella zoster, 191
- Fat transplantation, for rhytides. *See* *Rhytides*.
- Fibroblast growth factor, in wound healing, 51
- Fibroblasts, in dermal architecture, 433
- Fibrohistiocytic lesions, CD34 antigen expression in, 165-168
- Fibrous lesions, CD34 antigen expression in, 165-168
- Fibrovascular lesions, oral, CD34 antigen expression in, 172-173
- Finasteride, for androgenetic alopecia, 41
- Fine-needle aspiration, of necrotizing fasciitis, 216
- Flaps, in wound healing, 53
- Flashlamp-pumped pulsed dye lasers. *See also* *Laser therapy*.
 - basic principles of, 366
 - complications of, 526-527
- Fluconazole, for onychomycosis, 129-130
- Flukes, in world travelers, 290-291
- 5-Fluorouracil, for human papillomavirus infections, 192-193, 222, 335-336
- Flutamide, for androgenetic alopecia, 40
- Follicular degeneration, in persons of color, 689
- Follicular hyperkeratinization, in acne, 98-99
- Folliculitis, diagnosis and treatment of, 345-346
 - in immunocompromised host, 296
 - with HIV infection, 272, 273
- Food and Drug Administration guidelines, for drugs during pregnancy and lactation, 197-198
- Forehead, rhytides in, botulinum A exotoxin injection for, 605
- Foscarnet, for cytomegalovirus infection, with HIV infection, 267
 - for herpes simplex, 191
 - with HIV infection, 268
 - for Kaposi's sarcoma, 184
- Fournier's gangrene, clinical features of, 215
 - risk factors for, 214
- Fumaric acid, for psoriasis, 62
- Fungal infections, in immunocompromised host. *See* *immunocompromised host*.

with HIV infection. *See* *HIV infection*.

- Ganciclovir, for cytomegalovirus infection, with HIV infection, 267
- Gangrene, Fournier's, clinical features of, 215
 - risk factors for, 214
- Gardnerella vaginitis, diagnosis and treatment of, 243-244
- Gene therapy, advances in, 27-35
 - candidate diseases, 28-29
 - ex vivo gene transfer to skin, 29-30
 - experimental model systems, 33-34
 - gene transfer methods, 30-32
 - in vivo, 32
 - barriers to, 32-33
 - historical aspects of, 27-28
 - safety of, 34
- Genetic mosaicism, in children, 116
- Genital herpes, diagnosis and treatment of, in females, 233-234
- Genital ulcers, diagnosis and treatment of, 223
 - in females, 233-239
 - chancroid and, 234-237
 - genital herpes and, 233-234
 - granuloma inguinale and, 237-238
 - lymphogranuloma venereum and, 238-239
- Genital warts, diagnosis and treatment of, 221-223
- Glabellar area, rhytides in, botulinum A exotoxin injection for, 604
- Glucocorticoids, and cutaneous surgery, in elderly, 586
 - for androgenetic alopecia, 40-41
- Glycerol thioglycolate, and contact dermatitis, 145-146
- Glycolic acid, in medium-depth chemical peels, 21
 - in superficial chemical peels, 19-20
- Gold, and contact dermatitis, 142, 144
- Gold vapor lasers. *See also* *Laser therapy*.
 - in photodynamic therapy, 508
- Gonadotropin-releasing hormone agonists, for androgenetic alopecia, 41-42
- Gonorrhea, diagnosis and treatment of, 239-240
- Gorlin's syndrome, photodynamic therapy for, 513
- Grafts, in wound healing. *See* *Wound healing*.
- Granuloma inguinale, diagnosis and treatment of, 227-228
 - in females, 237-238
- Griseofulvin, drug interactions with, 538
 - during pregnancy and lactation, 200
- Group A *Streptococcus* infection, in necrotizing fasciitis, 214
 - with varicella, 260
- Growth factors, and androgens, in acne, 101
 - in wound healing, 49-52
 - with antiviral therapy and chemotherapy, for Kaposi's sarcoma, 181
- Hair products, and contact dermatitis, 145
- Hair removal, laser-assisted, 6, 15, 469-477
 - hair follicle embryology and anatomy in, 469
 - hair growth phases in, 469-470
 - photodynamic therapy in, 475-476
 - Q-switched Nd:YAG lasers in, 473-474
 - Q-switched ruby lasers in, 474-475
 - versus electrolysis and thermolysis, 470-471
 - applications of, 472
 - epilation techniques in, 471-472
 - nonlaser light in, 475

- Hair transplantation, in persons of color, 692
 laser-assisted, 5-6, 479-486
 safety of, 483-485
 techniques for, 480-483
- Heliotherapy, for vitiligo vulgaris, 73
- Helminthic infections, in world travelers. See *Infectious diseases*.
- Hemangiomas, laser therapy for, 2-3, 14, 380-381
- Hematoporphyrin derivative, in photodynamic therapy, 515
- Hemostasis, and cutaneous surgery, in elderly, 585-586
- Heparin, and cutaneous surgery, in elderly, 585-586
- Hepatitis B, treatment of, 189-190
- Herpes simplex, diagnosis and treatment of, 191-192, 223-224
 genital, in females, 233-234
 laser skin resurfacing and, 441, 530
 with HIV infection, 268
- Herpes zoster, with HIV infection, 268-269
- Herpesvirus, and Kaposi's sarcoma, 179-180
- Hirsutism, etiology of, 470
- Histamine, receptor antagonists, for psoriasis, 61
- Histiocytosis, Langerhans cell, in children, 117
- Histoplasmosis, in immunocompromised host, 301-302
 with HIV infection, 277
- HIV infection. See also *Immunocompromised host*.
 infectious diseases in, 267-283
 bacterial, 272-275
 bacillary angiomatosis, 273-274
 mycobacterial infections, 274-275
Pseudomonas aeruginosa infection, 273
Staphylococcus aureus infection, 272
 syphilis, 275
 fungal, 277-278
 cryptococcosis, 277
 histoplasmosis, 277
 sporotrichosis, 277-278
 parasitic, 275-277
Pneumocystis carinii infection, 276-277
 scabies, 275-276
 viral, 267-272
 cytomegalovirus, 267
 herpes simplex, 268
 herpes zoster, 268-269
 human papillomavirus infections, 270-272
 molluscum contagiosum, 269-270
 oral hairy leukoplakia, 269
 treatment of, 193-194
 antiretroviral therapy in. See *Antiretroviral therapy*.
- Hookworm infections, in world travelers, 287
- Hormonal therapy, for aging skin, 565-566
- Hot tub folliculitis, diagnosis and treatment of, 345-346
- Hot-comb alopecia, in persons of color, 689
- Human growth hormone, in wound healing, 52-53
- Human herpesvirus 8, and Kaposi's sarcoma, 179-180
- Human immunodeficiency infection. See *HIV infection*.
- Human papillomavirus infections, 331-340
 clinical features of, 332-333
 diagnosis of, 222
 treatment of, 192-193, 222-223, 334-339
 acids in, 335
 antiviral therapy in, 337-339
 chemotherapy in, 335-337
 freezing in, 335
 immunomodulatory agents in, 337-339
 laser therapy in, 490-491, 493-494
 photodynamic therapy in, 515-516
 rationale for, 333-334
 surgical, 334-335
 viral structure in, 331-332
 with HIV infection, 270-272
- Hydroquinone, as bleaching agent, before medium-depth chemical peels, 23, 691
- Hydroxyzine, during pregnancy and lactation, 200
- Hyperbaric oxygenation, for necrotizing fasciitis, 217-218
 in wound healing, 53
- Hyperpigmentation, laser skin resurfacing and, 441, 455, 530-531, 579
- Hypertension, and cutaneous surgery, in elderly, 584
- Hypertrichosis, etiology of, 470
- Hypertrophic scars, wound healing in, 54
- Hypopigmentation, laser skin resurfacing and, 455, 531
- Ibuprofen, during pregnancy and lactation, 200
- Imidazoles, drug interactions with, 538-539
- Imiquimod, for human papillomavirus infections, 222, 337-338
- Immunocompromised host. See also *HIV infection*.
 fungal infections in, 295-305
 deep mycoses, 298-303
 aspergillosis, 299
 coccidioidomycosis, 300-301
 cryptococcosis, 300
 histoplasmosis, 301-302
 mucormycosis, 303
Penicillium marneffei, 302
 sporotrichosis, 302-303
 systemic candidiasis, 298-299
 risk factors for, 295-296
 superficial mycoses, 296-298
 candidiasis, 298
 dermatophytosis, 296, 298
- Immunofluorescent assays, of Lyme disease, 250
- Immunomodulatory agents, for human papillomavirus infections, 337-339
- Immunosuppression, and cutaneous surgery, in elderly, 586-587
 and Kaposi's sarcoma, 179
- Immunotherapy, for cutaneous malignant melanoma, 13
 for psoriasis, 63-65
- Impetigo, diagnosis and treatment of, 341-343
 with HIV infection, 272
- Implants, osseointegrated, for aging dentition, 675-676
- Indinavir, for HIV infection, 324-326
- Infections, laser skin resurfacing and, 25, 441, 455
- Infectious diseases, antiretroviral therapy for. See *Antiretroviral therapy*.
- bacterial. See *Bacterial infections*.
- Borrelia burgdorferi* infections. See *Borrelia burgdorferi infections*.
- exanthematous diseases. See *Exanthematous diseases*.
- genital ulcers. See *Genital ulcers*.
- human papillomavirus infections. See *Human papillomavirus infections*.
- in immunocompromised host. See *Immunocompromised host*.
- in world travelers, 285-293
 ectoparasitic, 286-287
 helminthic, 287-291
 cutaneous larva migrans, 287-288
 intestinal nematodes, 287
Strongyloides stercoralis, 288, 290
 trematodes, 290-291
 protozoal, 291-293
 leishmaniasis, 291-293
 necrotizing fasciitis. See *Necrotizing fasciitis*.
- rickettsialpox. See *Rickettsialpox*.

Infectious diseases (*Continued*)

- sexually transmitted diseases. See *Sexually transmitted diseases*.
- spider bites. See *Spider bites*.
- vaginitides. See *Vaginitides*.
- with HIV infection. See *HIV infection*.
- Infrared coagulation, for human papillomavirus infections, 192
- Injectable bovine collagen, for rhytides. See *Rhytides*.
- Insulin-like growth factor, and androgens, in acne, 101
- Interferons, during pregnancy and lactation, 200
 - for human papillomavirus infections, 193, 223, 337
 - for Kaposi's sarcoma, 181, 182
- Interleukins, for cutaneous T-cell lymphoma, 154-155
- Isotretinoin, and androgens, in acne, 101-102
 - for acne, 105-106
- Itraconazole, for onychomycosis, 127-129
- Ivermectin, for scabies, 229

- Jessner's solution, in medium-depth chemical peels, 20-21, 23
- in superficial chemical peels, 20, 571

Kaposi's sarcoma, 177-178

- CD34 antigen expression in, 161, 164-165
- pathogenesis of, 177-180
 - genetic factors in, 178-179
 - hormonal aspects of, 179
 - human herpesvirus 8 in, 179-180
 - immunosuppression in, 179
- photodynamic therapy for, 515
- treatment of, 180-184, 194
 - local therapy in, 180-181
 - new drugs in, 183-184
 - retinoids in, 182-183
 - systemic therapy in, 181-182

Kawasaki syndrome, in children, 262-263

Keloids, laser therapy for, 421

wound healing in, 54

Keratoses, actinic, laser therapy for, 494-495

- photodynamic therapy for, 514

seborrheic, laser therapy for, 496

Krypton lasers. See also *Laser therapy*.

basic principles of, 365

complications of, 523

KTP lasers. See also *Laser therapy*.

basic principles of, 366-367

complications of, 523

Lactation, dermatologic drug use during. See *Dermatologic drugs*.

Lamivudine, for HIV infection, 323-324

Langerhans cell histiocytosis, in children, 116-117

Larva migrans, in world travelers, 287-288

Laser therapy. See also *Lasers*.

advances in, 1-8

- for capillary hemangiomas, 2-3, 14

- for facial wrinkles, 5

- for hair removal, 6

- for hair transplantation, 5-6

- for human papillomavirus infections, 192

- for in vivo skin imaging, 6

- for Kaposi's sarcoma, 181

- for leg veins, 3

- for pigmented lesions, 4-5, 15

- for port wine stains, 1-2, 14-15

- for scars, 3, 14

- for skin resurfacing, 25

- for striae, 3

- for tattoos, 5

- for warts, 4, 14

- for wound healing, 54

complications of, 521-534

- argon lasers, 522

- argon-pumped tunable dye lasers, 522-523

- continuous wave carbon dioxide lasers, 523

- copper vapor and copper bromide lasers, 523, 526

- flashlamp-pumped pulsed dye lasers, 526-527

- krypton lasers, 523

- KTP lasers, 523

- pulsed dye lasers, 527

- pulsed mode carbon dioxide lasers, 529-531

- Q-switched alexandrite lasers, 528

- Q-switched Nd:YAG lasers, 528-529

- Q-switched ruby lasers, 527-528

for acquired vascular lesions. See *Acquired vascular lesions*.

for atrophic scars. See *Atrophic scars*.

for dermal lesions. See *Dermal lesions*.

for epidermal lesions. See *Epidermal lesions*.

for hemangiomas, 380-381

for human papillomavirus infections, 334-335

for molluscum contagiosum, with HIV infection, 270

for pigmented lesions. See *Pigmented lesions*.

for port-wine stains. See *Port-wine stains*.

for rhytides. See *Rhytides*.

for scars and striae. See *Scars and striae*.

for tattoos. See *Tattoos*.

for warts. See *Warts*.

in hair removal. See *Hair removal*.

in hair transplantation. See *Hair transplantation*.

Lasers. See also *Laser therapy*.

basic principles of, 355-372

- argon lasers, 362-364

- argon-pumped dye and krypton lasers, 365

- carbon dioxide lasers, 361-362

- continuous wave visible light lasers, 362

- copper vapor lasers, 364-365

- electromagnetic radiation, 355

- flashlamp-pumped pulsed dye lasers, 366

- high energy and focusability, 358

- KTP lasers, 366-367

- laser time dependence, 361

- long pulsed dye lasers, 366

- mechanical effects, 360

- monochromaticity, 357

- pigment lasers, 367-368

- pigmented lesion dye lasers, 370

- Q-switched alexandrite lasers, 369-370

- Q-switched Nd:YAG lasers, 368-369

- Q-switched ruby lasers, 368

- radiometry, 358

- selective thermolysis, 360-361

- skin optics, 358-360

- spatial coherence, 357-358

- spontaneous and stimulated emission, 355-357

- thermal effects, 360

in photodynamic therapy. See *Photodynamic therapy*.

Leg telangiectasia, laser therapy for, 3, 393-395

Leishmaniasis, in world travelers, 291-293

Lentigines, laser therapy for, 496

Lentigo maligna, laser therapy for, 495

Lindane, for scabies, with HIV infection, 276

Linear IgA bullous dermatosis, anti-inflammatory drugs for, 700

- Liposuction, in persons of color, 692
tumescence, advances in, 15-16
- Lips, rejuvenation surgery for, 665-668
- Loop electrosurgical excision procedure, for human papillomavirus infections, 334
- Loviride, for HIV infection, 324
- Loxosceles reclusa* spider bites. See *Spider bites*.
- Lyme disease. See *Borrelia burgdorferi* infections.
- Lymphangioma circumscriptum, laser therapy for, 499
- Lymphangitis, diagnosis and treatment of, 344-345
- Lymphocytoma, borreliosis, clinical features of, 253
- Lymphogranuloma venereum, diagnosis and treatment of, 227
in females, 238-239
- Lymphoma, cutaneous T-cell. See *Cutaneous T-cell lymphoma*.
- Male pattern alopecia, restoration surgery for, 609-622
combination micrografting and single-hair transplantation, 618, 621
consultation for, 611
donor area in, 613-614
graft planting in, 617
historical aspects of, 609-611
pattern and hairline design in, 616
philosophy of, 611-613
postoperative care for, 617-618
recipient site in, 616-617
results of, 621-622
technique for, 614-616
- Malignant lesions, in persons of color, 690
- Malignant melanoma, cutaneous, dermatologic surgery for. See *Dermatologic surgery*.
- Measles, in children, 257-259
- Melanocyte transplantation, for vitiligo vulgaris, 73
- Melanocytic lesions, CD34 antigen expression in, 172
- Melanoma, in children. See *Pediatric dermatology*.
photodynamic therapy for, 515
- Melasma, in persons of color, 690-691
- Merkel's cells, in vitiligo vulgaris, 71
- Metalloproteinases, for Kaposi's sarcoma, 183
- Metals, and contact dermatitis, 142, 144
- Methimazole, for psoriasis, 61
- 5-Methoxypsoralen, for psoriasis, 60
- Methylchloroisothiazolinone/methylisothiazolinone, and contact dermatitis, 145
- Methyldibromoglutaronitrile/phenoxyethanol, and contact dermatitis, 144-145
- Metronidazole, during pregnancy and lactation, 200
for trichomoniasis, 243
- Microcystic adnexal carcinoma, CD34 antigen expression in, 169-170
- Minoxidil, during pregnancy and lactation, 200
for androgenetic alopecia, 41
- Missouri fiddle back spider bites. See *Spider bites*.
- Molluscum contagiosum, diagnosis and treatment of, 190, 228-229
with HIV infection, 269-270
- Monilial vaginitis, diagnosis and treatment of, 244
- Morphea, CD34 antigen expression in, 173-174
- Mosaicism, genetic, in children, 116
- Mouth, aging of, pathogenesis of, 665
- Mucormycosis, in immunocompromised host, 303
- Muscle lesions, CD34 antigen expression in, 172
- Mycobacterial infections, with HIV infection, 274-275
- Mycoses, in immunocompromised host. See *Immunocompromised host*.
- Mycosis fungoides, photodynamic therapy for, 514-515
- Myiasis, in world travelers, 286-287
- Nail products, and contact dermatitis, 146
- Nail surgery, laser-assisted, 500
- Naproxen, during pregnancy and lactation, 200
- Narcotics, during pregnancy and lactation, 201
- Nd:YAG laser therapy, for café-au-lait macules, 4
for pigmented lesions, 15
for tattoos, 5
in hair removal, 15
- Necrotizing fasciitis, 213-220
bacteriology in, 213-214
clinical features of, 215
diagnosis and treatment of, 215-218, 346-348
prevention of, 218-219
risk factors for, 214-215
- Nematodes, intestinal, in world travelers, 287
- Neural lesions, CD34 antigen expression in, 170-172
- Neuralgia, postherpetic, treatment of, 191
- Nevi, acquired, in children, 112-113
congenital melanocytic, in children, 111-112
laser therapy for, 4-5, 15, 496
- Nevirapine, for HIV infection, 324
- Nickel, and contact dermatitis, 144
- Nicotine, and cutaneous surgery, in elderly, 586
- Nongonococcal urethritis, diagnosis and treatment of, 240-242
- Nonmelanoma skin cancer, oncogenes in, 16
- Nonnucleoside reverse transcriptase inhibitors, for HIV infection, 324
- Nonsteroidal anti-inflammatory drugs, and cutaneous surgery, in elderly, 585-586
during pregnancy and lactation, 200
for autoimmune skin diseases. See *Autoimmune skin diseases*.
- Nose, rejuvenation surgery for. See *Rhinoplasty*.
- Nucleoside analogues, combinations of, for HIV infection, 323-324
- Nutritional therapy, for necrotizing fasciitis, 218
- Onychomycosis, 121-135
comparative studies of treatments for, 130
in immunocompromised host, 298
oral antifungal agents for, 125-130
fluconazole, 129-130
itraconazole, 127-129
terbinafine, 125-127
topical and surgical therapies for, 124-125
topical antifungal agents for, 121-124
amorolfine, 122-123
bifonazole and urea combination, 124
ciclopirox olamine, 123-124
tioconazole nail solution, 124
- Opioid narcotics, during pregnancy and lactation, 201
- Oral and maxillofacial surgery, for aging dentition, 676-678
- Oral contraceptives, for androgenetic alopecia, 41
- Oral fibrovascular lesions, CD34 antigen expression in, 172-173
- Oral hairy leukoplakia, with HIV infection, 269
- Oral submucosa, CD34 antigen expression in, 172-173
- Organ transplant recipients, fungal infections in. See *Immunocompromised host*.
- Osseointegrated implants, for aging dentition, 675-676
- Otitis externa, with HIV infection, 273
- Oxygen, in photodynamic therapy, 511

- Oxygenation, hyperbaric, in wound healing, 53
- Pacemakers, and cutaneous surgery, in elderly, 587
- Palladium, and contact dermatitis, 144
- Papular-purpuric gloves and socks syndrome, in children, 261
- Parasitic infections, with HIV infection. See *HIV infection*.
- Parvovirus B19, in children, 260-261
- Patch testing, for contact dermatitis. See *Contact dermatitis*.
- Pediatric dermatology, 111-119
 - genetic mosaicism, 116
 - juvenile xanthogranuloma, 117
 - Langerhans cell histiocytosis, 116-117
 - melanoma and other melanocytic lesions, 111-116
 - acquired nevi and other pigmented lesions, 112-113
 - congenital melanocytic nevi, 111-112
 - in high risk groups, 113-114
 - prevention of, 115-116
 - pyoderma gangrenosum, 118
- Pelvic inflammatory disease, chlamydial infections and, 241
 - treatment of, 242
- Pemphigus, anti-inflammatory drugs for, 699-700
 - bullous pemphigus, 696-698
 - cicatricial pemphigus, 698-699
- Penicillium marneffei* infection, in immunocompromised host, 302
- Pentavalent antimony, for leishmaniasis, 292-293
- Pentosan polysulfate, for Kaposi's sarcoma, 183
- Pentoxyfylline, for HIV infection, 194
- Perioral area, aging of, pathogenesis of, 663
 - rejuvenation surgery for, 665-672
 - lip surgery, 665-668
 - technique for, 668, 670-672
- Permethrin, for scabies, 229
- Persons of color, aging face in, 687-693
 - cosmetic surgery in, 691-693
 - blepharoplasty, 692-693
 - chemical peels, 692
 - facialplasty, 693
 - hair transplantation, 692
 - liposuction, 692
 - photographic documentation of, 693
 - rhinoplasty, 693
 - cosmetics for, 691
 - cutaneous conditions in, 685-691
 - dermatosis papulosis nigra, 688-689
 - hot-comb alopecia, 689
 - increased facial hair, 689-690
 - malignant lesions, 690
 - melasma, 690-691
 - seborrheic dermatitis, 690
 - xanthelasma, 690
- Pharyngitis, gonococcal, diagnosis and treatment of, 240
- Phenol, in chemical peels, versus other techniques, 461
 - in deep chemical peels, 25, 573
 - in medium-depth chemical peels, 572
- Phenylalanine, for vitiligo vulgaris, 73
- Photoallergens, and contact dermatitis, 140-142
- Photobleaching, in photodynamic therapy, 511
- Photochemotherapy, extracorporeal, with electron beam radiotherapy, for cutaneous T-cell lymphoma, 154
 - with ultraviolet A light, for cutaneous T-cell lymphoma, 153-154
- Photoderm VL therapy, for acquired vascular lesions, 388, 394-395
- Photodynamic therapy, 507-519
 - advances in, 15
 - adverse effects of, 516
 - aminolevulinic acid in, 509-510
 - benzoporphyrin derivative verteporfin in, 510
 - for actinic keratoses, 514
 - for alopecia, 515
 - for basal cell carcinoma, 511-513
 - for basal cell nevus syndrome, 513
 - for Bowen's disease, 513
 - for human papillomavirus infections, 515-516
 - for Kaposi's sarcoma, 515
 - for melanoma, 515
 - for mycosis fungoides, 514-515
 - for pruritus and psoriasis, 60-61, 515
 - with HIV infection, 194
 - for skin metastases, 514
 - for squamous cell carcinoma, 513
 - in hair removal, 475-476
 - light sources in, 507-508
 - mechanism of action of, 510-511
 - porfimer sodium in, 508-509
 - tin ethyl etiopurpurin in, 510
- Photosensitivity, photodynamic therapy and, 516
- Physicians' Desk Reference guidelines, for drugs during pregnancy and lactation, 198
- Pigment lasers. See also *Laser therapy*.
 - basic principles of, 367-368
- Pigmented lesion dye lasers. See also *Laser therapy*.
 - basic principles of, 370
- Pigmented lesions, dermoscopy of. See *Dermoscopy*.
 - in children, 112-113
 - laser therapy for, 4-5, 15, 397-407
 - green light nonpulsed lasers in, 399, 402, 405
 - green light pulsed lasers in, 399, 402, 405
 - near-infrared pulsed lasers in, 402, 405
 - red light pulsed lasers in, 399-402, 405
- Pityrosporum* infections, in immunocompromised host, 296
- Plain films, of necrotizing fasciitis, 215
- Platelet factor, for Kaposi's sarcoma, 183
- Platelet-derived growth factor, in wound healing, 51-52
- Pneumocystis carinii* infection, with HIV infection, 276-277
- Podophyllin, during pregnancy and lactation, 200
 - for human papillomavirus infections, 222, 336
 - with HIV infection, 271
- Podophyllotoxin, for molluscum contagiosum, 190
- Poikiloderma of Civatte, laser therapy for, 391-392
- Poison ivy, and contact dermatitis, 144
- Poison oak, and contact dermatitis, 144
- Polymerase chain reaction, in Lyme disease, 251
- Porfimer sodium, in photodynamic therapy, 508-509, 511, 513
- Port-wine stains, laser therapy for, 1-2, 14-15, 373-377
 - argon lasers in, 373-375
 - argon-pumped dye lasers in, 377
 - carbon dioxide lasers in, 377
 - copper vapor lasers in, 377
 - krypton lasers in, 377
 - KTP lasers in, 377
 - long pulsed dye lasers in, 375-377
 - Nd:YAG lasers in, 377
- Positron emission tomography, of cutaneous malignant melanoma, 12
- Pregnancy, dermatologic drug use during. See *Dermatologic drugs*.
- Premarin cream, for aging skin, 565
- Preservatives, and contact dermatitis, 144-145
- Proctitis, gonococcal, diagnosis and treatment of, 240, 242

- Prograf, for psoriasis, 64
- Propecia, for androgenetic alopecia, 41
- Propionibacterium acnes*, in acne, 103-104
- Propranolol, and cutaneous surgery, in elderly, 587
- Propylthiouracil, for psoriasis, 61
- Prostaglandins, in wound healing, 53
- Prosthetic joint infections, chemoprophylaxis for, and cutaneous surgery, in elderly, 588-589
- Protease inhibitors, for HIV infection, 324-326
for Kaposi's sarcoma, 184
- Protozoal infections, in world travelers, 291-293
- Pseudoangiomatosis, eruptive, in children, 261-262
- Pseudomonas aeruginosa* infection, with HIV infection, 273
- Psoriasis, treatment of, 59-68
acitretin in, 62
antithyroid thioureylenes in, 61
capsaicin in, 61-62
fumaric acid in, 62
histamine, receptor antagonists in, 61
immunotherapy in, 63-65
photodynamic therapy in, 60-61, 515
tazarotene in, 63
vitamin D derivatives in, 62-63
zidovudine in, 61
with HIV infection, treatment of, 194
- Pulsed dye lasers. See *Laser therapy*.
basic principles of. See *Lasers*.
complications of, 526-531
- Pyoderma gangrenosum, in children, 118
- Pyogenic granulomas, laser therapy for, 392-393
- Pyruvic acid, in deep chemical peels, 25
- Q-switched alexandrite lasers. See also *Laser therapy*.
basic principles of, 369-370
complications of, 528
- Q-switched laser therapy, for café-au-lait macules, 4
for nevi, 4-5
for pigmented lesions, 15
for tattoos, 5
in hair removal, 15
- Q-switched Nd:YAG lasers. See also *Laser therapy*.
basic principles of, 368-369
complications of, 528-529
- Q-switched ruby lasers. See also *Laser therapy*.
basic principles of, 368
complications of, 527-528
- Radiotherapy, electron beam, for cutaneous T-cell lymphoma, 154
with extracorporeal photochemotherapy, for cutaneous T-cell lymphoma, 154
for Kaposi's sarcoma, 194
- Reactive neutrophilic dermatoses, anti-inflammatory drugs for, 704
- Recombinant human growth hormone, in wound healing, 52-53
- 5 α -Reductase activity, in acne, 102-103
- Reiter's syndrome, chlamydial infections and, 241
- Renova, for aging skin, 562
- Reproductive Toxicology guidelines, for drugs during pregnancy and lactation, 198
- Retin-A, for aging skin, 562
- 13-cis Retinoic acid, and androgens, in acne, 101-102
- Retinoids, for acne, 106-107
for aging skin, 561-562
for human papillomavirus infections, 336
for Kaposi's sarcoma, 182-183
for photoaging, 432
- Retrovir, for psoriasis, 61
- Retroviruses, gene transfer in, 31
- Reverse transcriptase inhibitors, for HIV infection. See *Antiretroviral therapy*.
- Rhinophyma, laser therapy for, 497
- Rhinoplasty, 659-664
consultation for, 659-661
in persons of color, 693
postoperative care for, 664
technique for, 661, 663-664
- Rhytides, treatment of, 595-607
autologous fat transplantation in, 600-603
complications of, 602
fat storage for, 601
harvesting of, 600-601
indications for, 602
long-term results of, 602-603
reimplantation in, 601-602
technique for, 600
- botulinum A exotoxin in, 603-605
basic science of, 603-604
for crow's feet, 604
for forehead, 605
for glabellar area, 604
with other procedures, 605
- injectable bovine collagen in, 595-600
adverse reactions to, 599-600
formulation for, 595-596
maintenance of, 599
techniques for, 599
testing of, 596, 599
- laser resurfacing in, 431-447
anesthesia in, 442-444
carbon dioxide lasers in, 433, 434
complications of, 445
computer pattern generator in, 435, 436
histologic studies of, 460-464
laser-tissue interaction in, 459-460
patient selection for, 437-441
postoperative care for, 442
preoperative preparation for, 441-442
SilkTouch laser in, 433, 437
technique for, 434-437
UltraPulse laser in, 433
versus topical therapies, 432-433
wound care in, 444-445
- Rickettsialpox, 313-318
clinical features of, 314-315
diagnosis and treatment of, 315-317
differential diagnosis of, 317
epidemiology of, 313-314
histopathology of, 315
- Rifampin, during pregnancy and lactation, 200
- Ritonavir, for HIV infection, 324-326
- Rogaine, for androgenetic alopecia, 41
- Rosacea-associated telangiectasia, laser therapy for, 389-390
- Roundworm infections, in world travelers, 287
- RU58841, for androgenetic alopecia, 41
- Salicylic acid, during pregnancy and lactation, 200
- Salpingitis, chlamydial infections and, 241
- Sandimmune, for psoriasis, 63-64
- Saquinavir, for HIV infection, 324-326
- Scabies, diagnosis and treatment of, 229

- Scabies (*Continued*)
 with HIV infection, 275-276
- Scars and striae, due to acne, 104-105
 hypertrophic, wound healing in, 54
 laser therapy for, 3, 14, 419-429
 atrophic scars. *See Atrophic scars.*
 combination lasers in, 423
 flashlamp-pumped pulsed dye lasers in, 423
 historical aspects of, 420
 hypertrophic scars, 421
 keloids, 421
 postoperative care for, 423, 426
 preoperative evaluation for, 422-423
 striae distensae, 421-422
 technique for, 423
- Schistosomiasis, in world travelers, 290-291
- Scleroderma, CD34 antigen expression in, 173-174
- Seborrheic dermatitis, in persons of color, 690
- Seborrheic keratoses, laser therapy for, 496
- Sebum production, in acne, 99-104
- Selenium sulfide, during pregnancy and lactation, 200
- Sexually transmitted diseases, 221-232
 chancroid, 226-227
 genital ulcers. *See Genital ulcers.*
 genital warts, 221-223
 granuloma inguinale, 227-228
 herpes simplex, 223-224
 lymphogranuloma venereum, 227
 molluscum contagiosum, 228-229
 scabies, 229
 syphilis, 225-226
- SilkTouch laser. *See also Laser therapy.*
 in hair transplantation, 480, 481, 482
 in skin resurfacing, 433, 437, 450, 460
 histologic studies of, 461
- Silver sulfadiazine, during pregnancy and lactation, 201
- Skin cancer, laser therapy for, 495-496
 nonmelanoma, oncogenes in, 16
- Skin diseases, autoimmune. *See Autoimmune skin diseases.*
- Skin metastases, photodynamic therapy for, 514
- Skin substitutes, in wound healing. *See Wound healing.*
- Skin-directed therapy, for cutaneous T-cell lymphoma, 153-154
- Soft tissue tumors, CD34 antigen expression in, 173
- Spider angiomas, laser therapy for, 390-391
- Spider bites, 307-311
 black widow spiders, 310-311
 brown recluse spiders, 307-310
 clinical features of, 309-310
 treatment of, 310
 venom in, 309
 tarantulas, 311
 wolf spiders, 311
- Spirolactone, during pregnancy and lactation, 200
 for androgenetic alopecia, 39-40
- Sporotrichosis, in immunocompromised host, 302-303
 with HIV infection, 277-278
- Squamous cell carcinoma, photodynamic therapy for, 513
- Staphylococcal infections, laser skin resurfacing and, 441
 with HIV infection, 272
- Stavudine, for HIV infection, 193-194, 322-324
- Striae. *See Scars and striae.*
- Strongyloides stercoralis* infections, in world travelers, 288, 290
- Sulfonamides, during pregnancy and lactation, 201
- SurgiPulse laser. *See also Laser therapy.*
 in skin resurfacing, 460
 histologic studies of, 461, 464
- Syphilis, diagnosis and treatment of, 225-226
 in females, 234
 with HIV infection, 275
- Tacalcitol, for psoriasis, 62-63
- Tacrolimus, for psoriasis, 64
- Tagamet, for androgenetic alopecia, 40
- Tapazole, for psoriasis, 61
- Tarantula bites, management of, 311
- Tattoos, laser therapy for, 5, 409-417, 499-500, 527-528, 529
 anesthesia in, 415
 basic principles of, 409-410
 potential complications of, 410-411
 preoperative preparation for, 414-415
 pulsed carbon dioxide lasers in, 414
 Q-switched alexandrite lasers in, 414
 Q-switched Nd:YAG lasers in, 411, 414
 Q-switched ruby lasers in, 411
 technique for, 415
 wound care in, 415-416
- Tazarotene, for acne, 106
 for psoriasis, 63
- T-cell receptor peptide vaccines, for psoriasis, 65
- Teeth, aging, cosmetic options for. *See Aging dentition.*
- Telangiectasia, laser therapy for, facial, 388-389
 leg, 3, 393-395
 rosacea-associated, 389-390
- Teratogen Information System guidelines, for drugs
 during pregnancy and lactation, 198
- Terbinafine, drug interactions with, 539
 for onychomycosis, 125-127
- Thalidomide, for Kaposi's sarcoma, 183
- Thermolysis, in hair removal. *See Hair removal.*
- Tin ethyl etiopurpurin, in photodynamic therapy, 510
- Tinea versicolor, in immunocompromised host, 296
- Tioconazole nail solution, for onychomycosis, 124
- Tixocortol pivalate, in patch testing, for contact dermatitis, 141
- TNP-470, for Kaposi's sarcoma, 183
- Transforming growth factor beta, in wound healing, 50-51
- Trematodes, in world travelers, 290-291
- Tretinoin, during pregnancy and lactation, 202-203
 for photoaging, 432, 433
- Trichloroacetic acid, for human papillomavirus infections, 335
 for molluscum contagiosum, 190
 with HIV infection, 270
 in chemical peels, versus other techniques, 461
 in medium-depth chemical peels, 20-21, 23, 571-573
 in superficial chemical peels, 570-571
- Trichoepitheliomas, CD34 antigen expression in, 169-170
- Trichomoniasis, diagnosis and treatment of, 242-243
- Trimeprazine, during pregnancy and lactation, 201
- TRUE Test patch test, for contact dermatitis, 139-140
- TruPulse laser. *See also Laser therapy.*
 in skin resurfacing, 460
- Tuberculosis, cutaneous, with HIV infection, 274-275
- Tumescent liposuction, advances in, 15-16
- Tumor necrosis factor-alpha, in psoriasis, 65
- Tunable dye lasers, in photodynamic therapy, 507-508
- Tungiasis, in world travelers, 287
- Ulcers, genital. *See Genital ulcers.*

- UltraPulse laser. See also *Laser therapy*.
 in hair transplantation, 480, 481, 482
 in skin resurfacing, 433, 450, 452, 460
 histologic studies of, 461, 464
- Ultrasonography, in wound healing, 54
- Ultraviolet phototherapy, for pruritus and psoriasis, 60
 with HIV infection, 194
- Unilateral laterothoracic exanthem, in children, 261
- United States Pharmacopoeial Dispensing Information
 guidelines, for drugs during pregnancy and
 lactation, 198
- Urea and bifonazole combination, for onychomycosis,
 124
- Urethritis, gonococcal, diagnosis and treatment of, 239
 nongonococcal, diagnosis and treatment of, 240-242
- Vaccines, for cutaneous malignant melanoma, 13
- Vaginitides, infectious, 239-244
 candidiasis, 244
 chlamydial infections, 240-242
 gardnerella vaginitis, 243-244
 gonorrhea, 239-240
 trichomoniasis, 242-243
- Valaciclovir, for herpes simplex, 224
- Varicella, in children, 259-260
 group A *Streptococcus* infection with, 260
- Varicella zoster, treatment of, 190-191
- Vascular lesions, CD34 antigen expression in, 160-165
 laser therapy for, 1-3
- Vasculitis, anti-inflammatory drugs for, 702-704
- Venous lakes, laser therapy for, 393
- Vermilionectomy, for actinic cheilitis, 494
- Verrucae, treatment of, 192-193
- Vinca alkaloids, for Kaposi's sarcoma, 181
- Viral diseases, of skin, 189-196
 exanthems, 189
 hepatitis B, 189-190
 herpes simplex, 191-192
 HIV infection, 193-194
 human papillomavirus infections, 192-193
 Kaposi's sarcoma. See *Kaposi's sarcoma*.
 molluscum contagiosum, 190
 varicella zoster, 190-191
- Vitamin C, for aging skin, 564-565
- Vitamin D derivatives, for psoriasis, 62-63
- Vitamin therapy, for photoaging, 432-433
- Vitiligo vulgaris, 69-78
 autoimmune endocrine disorders and, 70-71
 genetics in, 69-70
 Merkel's cells in, 71
 pathogenesis of, 73-75
- physiology of depigmented epidermis in, 69
 treatment of, 71-73
- Warts, treatment of, 192-193
 laser therapy in, 4, 14, 489-494
 carbon dioxide lasers in, 489-491
 copper vapor lasers in, 492-493
 KTP lasers in, 493
 pulsed dye lasers in, 491-492
- Weil-Felix test, for rickettsialpox, 316
- Western immunoblots, of Lyme disease, 250
- Wolf spider bites, management of, 311
- World Health Organization guidelines, for drugs during
 pregnancy and lactation, 198
- Wound care, in laser therapy, for atrophic scars,
 452-453
 for epidermal lesions, 489
 for rhytides, 444-445
 for scars and striae, 423, 426
 for tattoos, 415-416
- Wound healing, advances in, 45-58
 autologous blood products, 52
 biologic skin substitutes, 45-49
 composite grafts, 46-49
 cultured epidermal allografts, 46
 cultured epidermal autografts, 45-46
 flaps, 53
 for keloids and hypertrophic scars, 54
 growth factors, 49-52
 hyperbaric oxygenation, 53
 physical modalities, 54
 platelet-derived wound healing formula, 52
 prostaglandins, 53
 recombinant human growth hormone, 52-53
 and cutaneous surgery, in elderly, 586-587
- Wrinkles, facial, laser therapy for, 5
- Xanthelasma, in persons of color, 690
- Xanthogranuloma, juvenile, 117
- Zalcitabine, for HIV infection, 193, 322-324
- Zidovudine, for HIV infection, 193, 320-324
 for psoriasis, 61
 with interferons, for Kaposi's sarcoma, 182
- Zostrix, for psoriasis, 61-62
- Zyderm. See *Rhytides, injectable bovine collagen for*.
- Zyplast. See *Rhytides, injectable bovine collagen for*.